Literature DB >> 22119373

Parameters for the Lyman Kutcher Burman (LKB) model of Normal Tissue Complication Probability (NTCP) for specific rectal complications observed in clinical practise.

Sarah L Gulliford1, Mike Partridge, Matthew R Sydes, Steve Webb, Philip M Evans, David P Dearnaley.   

Abstract

BACKGROUND AND
PURPOSE: The Normal Tissue Complication Probability (NTCP) for rectum is usually defined for late rectal bleeding. This study calculates NTCP parameter values for additional rectal toxicity endpoints observed in clinical practise.
MATERIALS AND METHODS: 388 patients from the multicentre MRC-RT01 prostate conformal radiotherapy trial (ISRCTN 47772397) were used to derive independent Lyman Kutcher Burman model (LKB) parameters for five late rectal toxicity endpoints: rectal bleeding, proctitis, stool frequency, loose stools and rectal urgency. The parameters were derived using maximum likelihood estimation. Bootstrap and leave-one-out methods were employed to test the generalisability of the results for use in a general population.
RESULTS: A consistent pattern of increasing value of TD50(1) for Grade 2 toxicity only compared to Grades 1 and 2 toxicity was observed for all endpoints. Parameter values varied between endpoints (particularly for the volume parameter n). TD50(1), m and n were 68.5 Gy (95% CI)(66.8-70.8), 0.15 (0.13-0.17) and 0.13 (0.10-0.17), respectively, for G2 rectal bleeding. Bootstrap and leave-one-out results showed that the rectal bleeding and proctitis parameter fits were extremely robust.
CONCLUSIONS: The variation between the values derived for different endpoints may indicate different patho-physiological responses of the rectum to radiation. Therefore different parameter sets would be required to predict specific rectal toxicity endpoints.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22119373     DOI: 10.1016/j.radonc.2011.10.022

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  21 in total

Review 1.  Radiogenomics and radiotherapy response modeling.

Authors:  Issam El Naqa; Sarah L Kerns; James Coates; Yi Luo; Corey Speers; Catharine M L West; Barry S Rosenstein; Randall K Ten Haken
Journal:  Phys Med Biol       Date:  2017-08-01       Impact factor: 3.609

2.  Image-guided radiotherapy of the prostate using daily CBCT: the feasibility and likely benefit of implementing a margin reduction.

Authors:  I F Maund; R J Benson; J Fairfoul; J Cook; R Huddart; A Poynter
Journal:  Br J Radiol       Date:  2014-10-29       Impact factor: 3.039

Review 3.  Reducing rectal injury during external beam radiotherapy for prostate cancer.

Authors:  Riccardo Valdagni; Tiziana Rancati
Journal:  Nat Rev Urol       Date:  2013-05-14       Impact factor: 14.432

4.  Dose/volume-response relations for rectal morbidity using planned and simulated motion-inclusive dose distributions.

Authors:  Maria Thor; Aditya Apte; Joseph O Deasy; Àsa Karlsdóttir; Vitali Moiseenko; Mitchell Liu; Ludvig Paul Muren
Journal:  Radiother Oncol       Date:  2013-11-11       Impact factor: 6.280

5.  Relationships between dose to the gastro-intestinal tract and patient-reported symptom domains after radiotherapy for localized prostate cancer.

Authors:  Maria Thor; Caroline E Olsson; Jung Hun Oh; Stine E Petersen; David Alsadius; Lise Bentzen; Niclas Pettersson; Ludvig P Muren; Ann-Charlotte Waldenström; Morten Høyer; Gunnar Steineck; Joseph O Deasy
Journal:  Acta Oncol       Date:  2015-09-04       Impact factor: 4.089

6.  Effect on therapeutic ratio of planning a boosted radiotherapy dose to the dominant intraprostatic tumour lesion within the prostate based on multifunctional MR parameters.

Authors:  S F Riches; G S Payne; N M Desouza; D Dearnaley; V A Morgan; S C Morgan; M Partridge
Journal:  Br J Radiol       Date:  2014-03-06       Impact factor: 3.039

7.  Estimates of Alpha/Beta (α/β) Ratios for Individual Late Rectal Toxicity Endpoints: An Analysis of the CHHiP Trial.

Authors:  Douglas H Brand; Sarah C Brüningk; Anna Wilkins; Katie Fernandez; Olivia Naismith; Annie Gao; Isabel Syndikus; David P Dearnaley; Alison C Tree; Nicholas van As; Emma Hall; Sarah Gulliford
Journal:  Int J Radiat Oncol Biol Phys       Date:  2021-01-04       Impact factor: 7.038

8.  Evaluating the predictive value of quantec rectum tolerance dose suggestions on acute rectal toxicity in prostate carcinoma patients treated with IMRT.

Authors:  E Elif Ozkan; Alper Ozseven; Z Arda Kaymak Cerkesli
Journal:  Rep Pract Oncol Radiother       Date:  2019-12-09

9.  Personalized Treatment Planning Automation in Prostate Cancer Radiation Oncology: A Comprehensive Dosimetric Study.

Authors:  Savino Cilla; Carmela Romano; Vittoria E Morabito; Gabriella Macchia; Milly Buwenge; Nicola Dinapoli; Luca Indovina; Lidia Strigari; Alessio G Morganti; Vincenzo Valentini; Francesco Deodato
Journal:  Front Oncol       Date:  2021-06-01       Impact factor: 6.244

10.  Quantification of the uncertainties within the radiotherapy dosimetry chain and their impact on tumour control.

Authors:  Matthew Bolt; Catharine H Clark; Andrew Nisbet; Tao Chen
Journal:  Phys Imaging Radiat Oncol       Date:  2021-06-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.